ERVW-1 and HIV-1 infection: In the VAX003 trial, rgp120 HIV-1 Env immunogens from subtypes B MN and CRF01_AE A244 strains were assessed for vaccine efficacy against HIV-1 infection [5] and Env proteins alone did not prevent HIV-1 infection nor delay the onset of AIDS in infected VAX003 vaccinees [5].